Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine

Anticancer Research

Volumn 29, Issue 5, 2009, Pages 1835-1840

  Pacetti, Paola ^a   Giovannetti, Elisa ^b   Mambrini, Andrea ^a   Nannizzi, Sara ^b   Orlandi, Massimo ^a   Tartarini, Roberta ^a   Del Freo, Alfonso ^a   Del Tacca, Mario ^b   Danesi, Romano ^b   Cantore, Maurizio ^a  

^a Carrara City Hospital   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Biliary tract carcinoma; Cisplatin; DNA repair proteins; Pharmacogenomic; Polymorphisms

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN;

ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CISPLATIN; DEOXYCYTIDINE; DNA-BINDING PROTEINS; ENDONUCLEASES; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 67650083149     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Goldstein DB, Tate SK and Sisodiya SM: Pharmacogenetics goes genomic. Nat Rev Genet 4: 937-947, 2003.
2. Jepsen P, Vilstrup H, Tarone RE, Friis S and Sørensen HT: Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002. J Natl Cancer Inst 99: 895-897, 2007.
3. Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y and Blumgart LH: Intrahepatic cholangiocarcinoma: resectability, recurrence pattern and outcomes. J Am Coll Surg 193: 384-391, 2001. (Pubitemid 32895979)
4. Jan YY, Yeh CN, Yeh TS and Chen TC: Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital. World J Gastroenterol 11: 1779-1784, 2005. (Pubitemid 40520767)
5. Kim ST, Park JO, Lee J, Lee KT, Lee JK, Choi SH, Heo JS, Park YS, Kang WK and Park K: Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 106: 1339-1346, 2006. (Pubitemid 43363912)
6. Olnes MJ and Erlich R: A review and update on cholangiocarcinoma. Oncology 66: 167-179, 2004.
7. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR and Wasan H: Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51: vi1-vi9, 2002. (Pubitemid 35216840)
8. Oberfield RA and Rossi RL: The role of chemotherapy in the treatment of bile duct cancer. World Surg 12: 105-108, 1998.
9. Ellis PA, Norman A, Hill A, O'Brien ME, Nicolson M, Hickish T and Cunningham D: Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer 31: 1594-1598, 1995.
10. Cantore M, Mambrini A, Fiorentini G, Rabbi C, Zamagni D, Caudana R, Pennucci C, Sanguinetti F, Lombardi M and Nicoli N: Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer 103: 1402-1407, 2005. (Pubitemid 40410735)
11. Eckel F and Schmid RM: Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96: 896-902, 2007. (Pubitemid 46452283)
12. Bosken CH, Wei Q, Amos CI and Spitz MR: An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 94: 1091-1099, 2002. (Pubitemid 34830729)
13. Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H and Sanchez-Cespedes M: DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 24: 4333-4339, 2006. (Pubitemid 46630792)
14. Khan SA, Thomas HC, Davidson BR and Taylor-Robinson SD: Cholangiocarcinoma. Lancet 366: 1303-1314, 2005.
15. Mambrini A, Guglielmi A, Pacetti P, Iacono C, Torri T, Auci A, Nicoli N, Orlandi M, Guadagni S, Fiorentini G and Cantore M: Capecitabine plus hepatic intra-arterial epirubicin and cisplatin in unresectable biliary cancer: a phase II study. Anticancer Res 27: 3009-3013, 2007. (Pubitemid 47228038)
16. Au WW, Salama SA and Sierra-Torres CH: Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 111: 1843-1850, 2003. (Pubitemid 37526965)
17. Suh KW, Kim JH, Kim do Y, Kim YB, Lee C and Choi S: Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene? Ann Surg Oncol 13: 1379-1385, 2006.
18. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T and Soria JC: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991, 2006. (Pubitemid 44343542)
19. Giachino DF, Ghio P, Regazzoni S, Mandrile G, Novello S, Selvaggi G, Gregori D, DeMarchi M and Scagliotti GV: Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res 13: 2876-2881, 2007. (Pubitemid 46849561)
20. Chung HH, Kim MK, Kim JW, Park NH, Song YS, Kang SB and Lee HP: XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer. Gynecol Oncol 103: 1031-1037, 2006. (Pubitemid 44821330)
21. Bewick MA, Conlon MS and Lafrenie RM: Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol 24: 5645-5651, 2006. (Pubitemid 46631304)
22. Liu B, Wei J, Zou Z, Qian X, Nakamura T, Zhang W, Ding Y, Feng J and Yu L: Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet 15: 1049-1053, 2007. (Pubitemid 47491460)
23. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN and Ajani JA: Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24: 3789-3798, 2006. (Pubitemid 46628477)
24. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS and Christiani DC: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22: 2594-2601, 2004. (Pubitemid 41103746)
25. de las Peñas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, Massuti B, Queralt C, Botia M, Garcia-Gomez R, Isla D, Cobo M, Santarpia M, Cecere F, Mendez P, Sanchez JJ and Rosell R: Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 17: 668-675, 2006.
26. Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, Ducreux M, Sarasin A and Praz F: ERCC1 codon 118 polymorphism is a predictive factor for the tumour response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11: 6212-6217, 2005. (Pubitemid 41262950)
27. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivanco G, Camps C, Botia M, Nuñez L, Sanchez-Ronco M, Sanchez JJ, Lopez-Brea M, Barneto I, Paredes A, Medina B, Artal A and Lianes P: Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15: 1194-1203, 2004. (Pubitemid 39199306)
28. Marsh S, Paul J, King CR, Gifford G, McLeod HL and Brown R: Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 25: 4528-4535, 2007. (Pubitemid 350035308)
29. Schmitz KJ, Lang H, Frey UH, Sotiropoulos GC, Wohlschlaeger J, Reis H, Takeda A, Siffert W, Schmid KW and Baba HA: GNAS1 T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma. Neoplasia 9: 159-165, 2007. (Pubitemid 46318374)
30. Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, Hirohashi S and Shibata T: Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98: 418-425, 2008. (Pubitemid 351161240)